- Conditions
- Multiple Myeloma
- Interventions
- Arlocabtagene Autoleucel
- Biological
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 33 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 2,034
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Venous Thromboembolism
- Interventions
- Apixaban, Rivaroxaban
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Hepatitis C
- Interventions
- Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 50
- States / cities
- Montgomery, Alabama • Beverly Hills, California • Coronado, California + 37 more
- Conditions
- Healthy Participants
- Interventions
- Rosuvastatin, Branebrutinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Chordoma
- Interventions
- Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery
- Other · Biological · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Bladder Cancer
- Interventions
- Gemcitabine,, Cisplatin, Cetuximab
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 14
- States / cities
- Duarte, California • Los Angeles, California • Stanford, California + 11 more
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Papillary Thyroid Cancer, Melanoma, Colorectal Adenocarcinoma
- Interventions
- CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, Nivolumab and Nal-IRI/5-FU/LV - Expansion
- Drug
- Lead sponsor
- Famewave Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 2 more
- Conditions
- Melanoma, Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 12
- States / cities
- Palm Springs, California • Jacksonville, Florida • Lake City, Florida + 9 more
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Nivolumab, Cisplatin, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Sue Yom
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Cancer
- Interventions
- Nivolumab, Subcutaneous nivolumab combined with hyaluronidase
- Drug · Combination Product
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Fort Myers, Florida
- Conditions
- Various Advanced Cancer
- Interventions
- Nivolumab, Ipilimumab, Relatlimab, Daratumumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 14
- States / cities
- Tampa, Florida • Atlanta, Georgia • Lutherville, Maryland + 9 more
- Conditions
- IgG4 Related Disease
- Interventions
- Obexelimab, Placebo
- Drug · Other
- Lead sponsor
- Zenas BioPharma (USA), LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 5
- States / cities
- Stanford, California • Naples, Florida • Atlanta, Georgia + 2 more
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mediastinal Large B-cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
- Interventions
- Bridging radiation therapy, Liso-cel, Post-infusion radiation
- Radiation · Biological
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Solid Tumor
- Interventions
- HuMax-IL8
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- BMS-275183
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 7
- States / cities
- Sacramento, California • New Haven, Connecticut • Atlanta, Georgia + 4 more
- Conditions
- New Onset Diabetes After Transplant, Kidney Transplantation
- Interventions
- Belatacept, Tacrolimus
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Multiple Myeloma
- Interventions
- Elotuzumab, Pomalidomide, Dexamethasone, Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 22
- States / cities
- Mobile, Alabama • Santa Barbara, California • Denver, Colorado + 17 more
- Conditions
- Atrial Fibrillation
- Interventions
- AF at Home
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Chapel Hill, North Carolina • Durham, North Carolina • Winston-Salem, North Carolina
- Conditions
- Advanced Solid Tumors
- Interventions
- BMS-986484, Nivolumab, Oxaliplatin, Capecitabine, Fluorouracil, Calcium folinate
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Los Angeles, California • Grand Rapids, Michigan + 2 more
- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer, Colon Cancer
- Interventions
- Regorafenib, Nivolumab
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 15
- States / cities
- Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more
- Conditions
- Melanoma
- Interventions
- Not listed
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 1,773 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Infections
- Interventions
- Lamivudine, Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Months to 15 Years
- Enrollment
- 740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 61 more
- Conditions
- Myasthenia Gravis
- Interventions
- Abatacept Injection
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 16 Years to 85 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland